The cardio‐renal‐metabolic role of the nod‐like receptor protein‐3 and senescence‐associated secretory phenotype in early sodium/glucose cotransporter‐2 inhibitor therapy in people with diabetes who have had a myocardial infarction

Elucidating a role for an SGLT2i in suppressing sterile inflammation will enhance understanding of how they can be used effectively to treat cardiorenal complications and will identify novel pathways for future intervention. Furthermore, the optimal timing of when to initiate SGLT2i therapy post-AMI is unclear. Correlating the level of protection to the onset of therapy in individuals with T2DM, AMI and at cardiovascular risk will establish if Empagliflozin provides greater benefit when intervention is initiated earlier.